Post by JHam on Jul 9, 2014 19:11:27 GMT
OncoSec Medical Incorporated is a drug-medical device and therapeutic company. The Company is focused on designing, developing and commercializing medical approaches for the treatment of solid tumors that have unmet medical needs or where approved therapies are inadequate based on their efficacy or side-effects. The Company’s OncoSec Medical System (OMS), a therapeutic approach, which is based on the use of an electroporation delivery device in combination with an approved chemotherapeutic drug and a DNA-based cytokine to treat solid tumors. In May 2013, two new drugs for metastatic melanoma Tafinlar and Mekinist were approved. Tafinlar and Mekinist are single-agent oral treatments for the treatment of unresectable metastatic melanoma.
Current state of things:
Thought I'd introduce a new company here that I have been reading up on the last few days. It was introduced to me by someone on Yahoo of all places, but so far I like what I see.
- Ticker symbol: ONCS (OTCMKTS)
- 244.39M o/s
- $148.47M market cap
- $.608 current share price
- $24.3M cash on hand as of Apr. 30, 2014
- $25.7M shareholder equity
- Quick summary -
They just did the biggest cash raise in the company's history. It's enough to get them through the next 12 months (finish Phase II and Phase IIb).
Their leading candidate is called ImmunoPulse, which is a mono therapy drug delivery platform used to attack late stage skin cancer (melanoma).
The science is pretty fascinating. In short, they inject an agent (DNA IL-12) into the tumor. Then use "electroporation" to open up microscopic pores in the tumor which allows the agent to enter. The agent then essentially "decloaks" the tumor allowing the immune system to identify the cancer cells and send CD8-T cells to go and attack the cancer.
They recently reported extremely positive late stage Phase II data at ASCO. 59% systemic response with 32% of those having an objective response and 11% achieving full remission. They are now looking to launch a Phase IIb this year using ImmunoPulse with a "checkpoint inhibitor" as they believe they will get greater results in later stage patients when ImunoPulse is used as a combined therapy.
The company believes that this platform can also be used for most other forms of cancer and plan on announcing other indications in the future.
I haven't opened a position yet, but am seriously considering it. Everything you need to know about this company is in this recent Annual Letter to Shareholders from the CEO:
www.heraldonline.com/2014/06/12/6050221/oncosec-medical-issues-annual.html
Current state of things:
Thought I'd introduce a new company here that I have been reading up on the last few days. It was introduced to me by someone on Yahoo of all places, but so far I like what I see.
- Ticker symbol: ONCS (OTCMKTS)
- 244.39M o/s
- $148.47M market cap
- $.608 current share price
- $24.3M cash on hand as of Apr. 30, 2014
- $25.7M shareholder equity
- Quick summary -
They just did the biggest cash raise in the company's history. It's enough to get them through the next 12 months (finish Phase II and Phase IIb).
Their leading candidate is called ImmunoPulse, which is a mono therapy drug delivery platform used to attack late stage skin cancer (melanoma).
The science is pretty fascinating. In short, they inject an agent (DNA IL-12) into the tumor. Then use "electroporation" to open up microscopic pores in the tumor which allows the agent to enter. The agent then essentially "decloaks" the tumor allowing the immune system to identify the cancer cells and send CD8-T cells to go and attack the cancer.
They recently reported extremely positive late stage Phase II data at ASCO. 59% systemic response with 32% of those having an objective response and 11% achieving full remission. They are now looking to launch a Phase IIb this year using ImmunoPulse with a "checkpoint inhibitor" as they believe they will get greater results in later stage patients when ImunoPulse is used as a combined therapy.
The company believes that this platform can also be used for most other forms of cancer and plan on announcing other indications in the future.
I haven't opened a position yet, but am seriously considering it. Everything you need to know about this company is in this recent Annual Letter to Shareholders from the CEO:
www.heraldonline.com/2014/06/12/6050221/oncosec-medical-issues-annual.html